a decade of treating hcv in patients with ongoing barriers to care
TRANSCRIPT
![Page 1: A Decade of Treating HCV in Patients with Ongoing Barriers to Care](https://reader031.vdocument.in/reader031/viewer/2022030214/588b1cce1a28ab78398b585d/html5/thumbnails/1.jpg)
The UC San Diego AntiViral Research Center sponsors weekly presentations by infectious disease clinicians, physicians and researchers. The goal of these presentations is to provide the most current research, clinical practices and trends in HIV, HBV, HCV, TB and other infectious diseases of global significance. The slides from the AIDS Clinical Rounds presentation that you are about to view are intended for the educational purposes of our audience. They may not be used for other purposes without the presenter’s express permission.
AIDS CLINICAL ROUNDS
![Page 2: A Decade of Treating HCV in Patients with Ongoing Barriers to Care](https://reader031.vdocument.in/reader031/viewer/2022030214/588b1cce1a28ab78398b585d/html5/thumbnails/2.jpg)
A"Decade"of"Trea,ng"HCV"in"Pa,ents"with"Ongoing"Barriers"to"Care
Edward&Cachay&MD,&MAS&
Associate&Professor&of&Clinical&Medicine&
October&16,&2015&&
![Page 3: A Decade of Treating HCV in Patients with Ongoing Barriers to Care](https://reader031.vdocument.in/reader031/viewer/2022030214/588b1cce1a28ab78398b585d/html5/thumbnails/3.jpg)
HCV"is"a"disease"of"the"disenfranchised"
2&
14&17& 19&
29&35&
50&
90&
0&
10&
20&
30&
40&
50&
60&
70&
80&
90&
100&
1&
%"HCV
"an(
body"posi(ve"
US&populaHon&
&AA&born&in&1950s&
Hospitalized&paHents&
Severely&mentally&ill&
Prisoners&Homeless&people&
People&IDU&≤&10&yrs&
People&IDU&>&10&yrs&
![Page 4: A Decade of Treating HCV in Patients with Ongoing Barriers to Care](https://reader031.vdocument.in/reader031/viewer/2022030214/588b1cce1a28ab78398b585d/html5/thumbnails/4.jpg)
February"2008
• Rates&of&hepaHHs&C&were&increasing&in&the&general&populaHon&and&~&10&Hmes&higher&among&HIV&infected&paHents.&
• HIV&coUinfected&paHents&with&hospital&inpaHent&care&consHtuted&7.5&Hmes&as&many&hospitalizaHons&and&incurred&2.9&Hmes&the&charges&in&1995,&relaHve&to&all&HIV&hospitalizaHons&and&charges.&&
• In&contrast&to&the&general&populaHon,&rates&in&HIV&infecHon&represented&incident&cases.&
&
Hepatology:"2005,"42:"1406J13"
![Page 5: A Decade of Treating HCV in Patients with Ongoing Barriers to Care](https://reader031.vdocument.in/reader031/viewer/2022030214/588b1cce1a28ab78398b585d/html5/thumbnails/5.jpg)
HCV&incidence&in&HIV&MSM&in&relaHonship&to&calendar&year&
Rate/&100UPY&
MetaUregression&Polynomial&fit&&&&&&&&&&(with&95%&CI)&
Year&of&esHmate&
![Page 6: A Decade of Treating HCV in Patients with Ongoing Barriers to Care](https://reader031.vdocument.in/reader031/viewer/2022030214/588b1cce1a28ab78398b585d/html5/thumbnails/6.jpg)
Tim"who"was"32yo"was"admiMed"to"our"ICU"in"April"2007
• Tim"suffered"a"massive"myocardial"infarc,on"resul,ng"in"severe"conges,ve"heart"failure.
• "Suspected"induced"by"intravenous"methamphetamine"use. • Tim"was"diagnosed"with"HIV"and"also"HCV. • Tim"had"history"of"bipolar""disorder,"he"acknowledged"a""prior"suicidal"aMempt"at"age"21"while"‘under"the"influence’.
• CD4:"450,""HIV"VL"load">750,000"copies/ml"(at"diagnosis) &&
![Page 7: A Decade of Treating HCV in Patients with Ongoing Barriers to Care](https://reader031.vdocument.in/reader031/viewer/2022030214/588b1cce1a28ab78398b585d/html5/thumbnails/7.jpg)
March"2008":"Referred"for"HCV"treatment"considera,on:
• HCV"genotype"3""and"HCV"viral"load"HCV"RNA"9’000,000 • He"had"started"HAART"2"months"prior • Grade"I"liver"enzyme"eleva,on,"albumin"4.6,"INR:"1.0"and"had"‘a#normal#looking#liver#on#a#CT#scan’"while"in"the"ICU.
• Tim"said"“my"liver"is"fine"and"does"not"bother"me"all”."
• Nick"has"Ryan"White"insurance
• Tim"was"at"the",me"on"a"rehabilita,on"program"in"San"Marcos."
&
![Page 8: A Decade of Treating HCV in Patients with Ongoing Barriers to Care](https://reader031.vdocument.in/reader031/viewer/2022030214/588b1cce1a28ab78398b585d/html5/thumbnails/8.jpg)
Thinking&of&HCV&treatment&opHons&in&2007,&was&Tim&a&good&candidate&for&HCV&therapy?&&
1. Yes&2. No&&
![Page 9: A Decade of Treating HCV in Patients with Ongoing Barriers to Care](https://reader031.vdocument.in/reader031/viewer/2022030214/588b1cce1a28ab78398b585d/html5/thumbnails/9.jpg)
The"conven,onal"approach:
• HCV>&3&considered&to&have&more&favorable&responses&to&PegUIFN&and&ribavarin&(&~50%).&
• CoUmorbidiHes&could&be&exacerbated&during&HCV&therapy.&
• Psychiatry&issues&would&likely&become&too&challenging.&
“&No&major&evidence&of&liver&fibrosis,&conHnue&rehabilitaHon,&treat&your&HIV,&follow&closely&with&your&PMD,&remain&absHnent&and&RTC&in&1&year…”&
![Page 10: A Decade of Treating HCV in Patients with Ongoing Barriers to Care](https://reader031.vdocument.in/reader031/viewer/2022030214/588b1cce1a28ab78398b585d/html5/thumbnails/10.jpg)
Survival&by&HCV&AnHbody&Status&at&Clinic&Entry,&adjusted&for&Entry&CD4.&Owen&Clinic,&n&=,&5,978&
![Page 11: A Decade of Treating HCV in Patients with Ongoing Barriers to Care](https://reader031.vdocument.in/reader031/viewer/2022030214/588b1cce1a28ab78398b585d/html5/thumbnails/11.jpg)
What"propor,on"of"HIV"pa,ents"with"known"HCV"and"in"HIV"care"were""treated"for"HCV"in"the"United"States"at"the"end"of"2010?
1.&Less&than&3%&
2.&5%&
3.&8%&
4.&15%&
5.&30%&
![Page 12: A Decade of Treating HCV in Patients with Ongoing Barriers to Care](https://reader031.vdocument.in/reader031/viewer/2022030214/588b1cce1a28ab78398b585d/html5/thumbnails/12.jpg)
In"average"in"less"than"2.5%"of"pa,ents"coJinfected"with"HIV/HCV"were"cured"of"HCV""at"the"end"of"2012
100%&paHent&with&known&HIV/HCV&
&
never&treated&
25%&adverse&events&
10%&lost&to&followUup&
35%&sustained&viral&response&
30%&virological&failure&
![Page 13: A Decade of Treating HCV in Patients with Ongoing Barriers to Care](https://reader031.vdocument.in/reader031/viewer/2022030214/588b1cce1a28ab78398b585d/html5/thumbnails/13.jpg)
Factors"that"contribute"to"low"HCV"treatment"uptake"among"HIV"coJinfected"pa,ent"s
Pa(ent"" &Provider"
Medical"system"
Limited&tesHng¢ers&
Low&№&providers&confident&delivering&HCV&
treatment&
Too&complex&percepHon:&A. PaHents&B. Management&
Depend&on&subUspecialty&clinic&
Too&much&paper&work:&A. PaHent&access&&B. Underinsured&
Low&reimbursement&incenHve&
Adapted from Grebely et al. 2013. JID; 207 (Suppl 1)
![Page 14: A Decade of Treating HCV in Patients with Ongoing Barriers to Care](https://reader031.vdocument.in/reader031/viewer/2022030214/588b1cce1a28ab78398b585d/html5/thumbnails/14.jpg)
The"problem"is"not"limited"to"the"USA
From 1947 HIV-infected patients included, with a median follow-up time of 107 months (IQR: 57–156), only 23% received treatment for HCV (456 patients)
Grint D et al. HIV Med. 2013;14:614-23
0.00"
1.00"2.00"
3.00"
4.00"
5.00"6.00"7.00"8.00"
9.00"
Incide
nce&pe
r&100&PYFU
&
1998" 2000" 2002" 2004" 2006" 2008" 2010"
Incidence&rate&of&uptake&of&HCV&treatment&in&EuroSIDA&by®ion&
South&
North&
West&
East&C&
East&&
Copyright © Edward Cachay MD, MAS.
![Page 15: A Decade of Treating HCV in Patients with Ongoing Barriers to Care](https://reader031.vdocument.in/reader031/viewer/2022030214/588b1cce1a28ab78398b585d/html5/thumbnails/15.jpg)
April"2008:"Shortage"in"staff"and"reimbursement"became"major"disincen,ves"for"on"site"subJspecialty"care"for"our"HCV/HIV"pa,ents."
HIV&provider&
Pharmacist&
Psychiatrist&
Substance&counselor&
UCSDGOwen"Hepa((s"Clinic"
is"born..."
Copyright © Edward Cachay MD, MAS.
![Page 16: A Decade of Treating HCV in Patients with Ongoing Barriers to Care](https://reader031.vdocument.in/reader031/viewer/2022030214/588b1cce1a28ab78398b585d/html5/thumbnails/16.jpg)
Our&Goal:&To&improve&the&efficiency&of&the&HCV&staging&process&of&paHents&coUinfected&with&HIV/HCV&and&to&increase&the&absolute&number&of&paHents&&who&start&and&complete&treatment&&for&HCV&at&any&given&Hme&point.&
![Page 17: A Decade of Treating HCV in Patients with Ongoing Barriers to Care](https://reader031.vdocument.in/reader031/viewer/2022030214/588b1cce1a28ab78398b585d/html5/thumbnails/17.jpg)
Owen"coJinfec,on"hepa,,s"clinic
![Page 18: A Decade of Treating HCV in Patients with Ongoing Barriers to Care](https://reader031.vdocument.in/reader031/viewer/2022030214/588b1cce1a28ab78398b585d/html5/thumbnails/18.jpg)
HIV/HCV"coJinfected"pa,ents"had"more"coJmorbid"condi,ons"
The&median&№&of&comorbid&condiHons&was&greater&for&persons&with&HCV&coUinfecHon&(p<0.0001)&
0%"
10%"
20%"
30%"
40%"
50%"
0" 1" 2" 3+"№"of"comorbid"condi(ons"
Percen
tage"with
"con
di(o
ns"
HIV&monoinfected&
HIV/HCV&
Goulet'et'al.'AIDS'2005;'19'(suppl'3):'S99:S105'Copyright © Edward Cachay MD, MAS.
n=&25,116&&
![Page 19: A Decade of Treating HCV in Patients with Ongoing Barriers to Care](https://reader031.vdocument.in/reader031/viewer/2022030214/588b1cce1a28ab78398b585d/html5/thumbnails/19.jpg)
Among"HIV/HCV"coJinfected"pa,ents"there"is"a"high"prevalent"of"low"health"literacy,"ongoing"substance"dependences,"neuropsychiatry""disorder"and"unstable"housing
Illegal&substance&use&
Neuropsychiatry&disease&Alcohol&dependence&
Poverty&
Cachay et al. AIDS Res Ther 2011, 8:e29
![Page 20: A Decade of Treating HCV in Patients with Ongoing Barriers to Care](https://reader031.vdocument.in/reader031/viewer/2022030214/588b1cce1a28ab78398b585d/html5/thumbnails/20.jpg)
HIV
control
BA
RR
IER
S
LIV
ER
status
Co-m
orbidities The Owen Hepatitis Co-Infection staging table of HCV among HIV-infected patients
Lesson"#1:"More"than"assessing"liver"fibrosis…
Copyright © Edward Cachay MD, MAS.
![Page 21: A Decade of Treating HCV in Patients with Ongoing Barriers to Care](https://reader031.vdocument.in/reader031/viewer/2022030214/588b1cce1a28ab78398b585d/html5/thumbnails/21.jpg)
The"‘CCR’"rule"and"prospec,ve"engagement"in"care:
• Commitment:&HIV&viral&load&undetectable&
• Consistency:&Follow&through&with&medical&&&&&
&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&recommendaHons&and&or&appointment&
• Reliability:&Avoid&‘no&shows’&,call&to&‘reschedule’.&
Copyright © Edward Cachay MD, MAS.
![Page 22: A Decade of Treating HCV in Patients with Ongoing Barriers to Care](https://reader031.vdocument.in/reader031/viewer/2022030214/588b1cce1a28ab78398b585d/html5/thumbnails/22.jpg)
Key"prac,cal"points
• No&reUschedule&penalty&for&late&arrivals&• Always&it&is&a&good&Hme&to&start&over&again&
• ‘Cutback’&as&much&as&you&can&but&‘come&back’&no&maqer&what&
• SD&needle&exchange&program&/&methadone&clinics&
![Page 23: A Decade of Treating HCV in Patients with Ongoing Barriers to Care](https://reader031.vdocument.in/reader031/viewer/2022030214/588b1cce1a28ab78398b585d/html5/thumbnails/23.jpg)
Clinic"visit"schedule"for"HIV"pa,ents"on"HCV"treatment"based"on"their"specific"barriers"and/or"medical"coJmorbidi,es"(in"weeks)
! 0! 1! 2! 3! 4! 5! 6! 7! 8! 9! 10! 11! 12! 14! 16! 18! 20! 22! 24! 26! 28! 30! 32! 34! 36! 40! 44! 48!
Group&1& ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! !
Pharmacists!! X! !!!!!!!!!X! !!!!!!!!!!X! ! ! ! X! ! ! ! X! ! X! ! X! ! X! ! X! ! X! ! X! X! ! X!
Providers! X! ! ! ! X! ! ! ! X! ! ! ! X! ! X! ! X! ! X! ! X! ! X! ! X! X! X! X!
Group&2& ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! !
Pharmacists! X! X! X! X! X! ! X! ! X! ! X! ! X! X! ! X! ! X! ! X! ! X! ! X! ! X! ! X!
Providers! X! ! ! ! X! ! ! ! X! ! ! ! X! ! X! ! X! ! X! ! X! ! X! ! X! ! X! X!
Group&3& ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! !
Pharmacists! X! X! ! X! ! X! ! X! ! X! ! X! ! ! X! X! X! X! X! ! X! ! X! ! X! ! X! X!
Providers! X! X! X! X! X! ! X! ! X! ! X! ! X! X! X! X! X! X! X! X! X! X! X! X! X! X! X! X!
!
Homeless1!
Group 1: patients without major significant medical comorbidity, social barriers and no ongoing illicit substance use Group 2: patients with ongoing substance use (including intravenous) and/or homelessness Group 3: patients with severe neuropsychiatry disease (including prior suicidal attempts) and/or medical comorbidity
Cachay et al, AIDS Res Ther. 2013 Mar 28;10(1):9
Lesson:&One&size&does¬&fit&all&
Copyright © Edward Cachay MD, MAS.
![Page 24: A Decade of Treating HCV in Patients with Ongoing Barriers to Care](https://reader031.vdocument.in/reader031/viewer/2022030214/588b1cce1a28ab78398b585d/html5/thumbnails/24.jpg)
What"happened"with"Tim?
05/2008&
No"show"
"Completed"Echocardiogram"
HCV&Treatment&iniHaHon&
1&2&
4&
5& SVR&
3.&HIV&VL&UD&
End&HCV&therapy&
Psych"
“ProspecHve&engagement&in&care”&
Copyright © Edward Cachay MD, MAS.
06/2008& 06/2008& 07/2008&07/2008&
Call"to"reGschedule"
07/2008& 08/2008& 08/2009&09/2008&
02/2010&
![Page 25: A Decade of Treating HCV in Patients with Ongoing Barriers to Care](https://reader031.vdocument.in/reader031/viewer/2022030214/588b1cce1a28ab78398b585d/html5/thumbnails/25.jpg)
‘Valida,on"of"the"HCV/HIV"primary"care"model"’
SubGspecialty"model (January"2005GMarch"2008)
N&=152
N&=&22
N&=&199
Ini(al" evalua(on
study inclusion
Received"HCV"treatment
N&=146
N&=39
Primary"care"Model (April"2008"–"June"2010)
N&=&195
Excluded"pa(ents"(n"="47) UEntered&on&HCV&treatment:&9 UUndetectable&HCV&viral&load:&13& UPursued&clinical&trial:&11 UIncomplete&staging:&10 UTreatment&beyond&3/08:&4
Excluded"pa(ents"(n"="49) UEntered&on&HCV&treatment:&7 UUndetectable&HCV&viral&load:&6 UPursued&clinical&trial:&2 UIncomplete&staging:&12 UTreatment&beyond&8/11:&22
Untreated"pa(ents"(n=130) UAdvanced&cirrhosis:&13&UU&Uncontrolled&AIDS:&9& UPaHent&choice:&19 UPrior&nonUresponse:&6 ULost&to&followUup:&45&U&Drug/alcohol:&8 UUnstable&psych:&12 U&Homelessness&/language&literacy:&18
Untreated"pa(ents"(n=107) UAdvanced&cirrhosis:&17&UUncontrolled&AIDS:&22& U&&PaHent&Choice:&29 U&&&Prior&nonUresponse:10 U&&&Lost&to&follow&up:&22 U&&&Unstable&psych:&5 U&&&&Drug/alcohol&use&&&U Homelessness&/language&literacy:& 1
U The&referral&rate&did¬&differ&during&the&two&periods&(0.10&vs.&0.12/paHentUyr,&p = 0.18).&
&U Similar&treatment&disconHnuaHon&rates&due&to&
adverse&events&(29%&vs.&16%),&loss&to&followUup&(8&vs.&8%),&Owen&vs&subUspecialty,&respecHvely.&
&U Increase&trend&to&higher&HCV&SVR&(44&vs.&35%)&
for&Owen&vs.&&SubUspecialty&model,&respecHvely.&
Cachay&et&al.&AIDS&Res&Ther.&2013&
![Page 26: A Decade of Treating HCV in Patients with Ongoing Barriers to Care](https://reader031.vdocument.in/reader031/viewer/2022030214/588b1cce1a28ab78398b585d/html5/thumbnails/26.jpg)
Clinic"Model HighGrisk"(n="17)
NonGhighGrisk""(n=31)
P"value
№&PaHents&with&Sustained&viral&response&(%) 5(29) 16(52) 0.14
№&PaHents&who&disconHnued&HCV&therapy&due&to&nonUviral&response&(%)
2(12) 7(23) 0.36
№&PaHents&who&disconHnued&HCV&therapy&due&to&treatmentUrelated&side&effects&(%)
6(35) 8(26) 0.49
№&PaHents&lost&to&followUup&(%) 3(18) 1(3) 0.08
Cachay et al, AIDS Res Ther. 2013 Mar 28;10(1):9
Early"preliminary"observa(ons:""Successful"HCV"treatment"of"HIV"pa(ents"with"ongoing"barrier"to"care"is"possible"
There&were&no&differences&between&groups&in&age,ðnicity,&liver&fibrosis,&proporHon&of&HCV&genotype,&baseline&laboratory&exams&,&HCV&RNA&,&CD&and&HIV&VL.&&
![Page 27: A Decade of Treating HCV in Patients with Ongoing Barriers to Care](https://reader031.vdocument.in/reader031/viewer/2022030214/588b1cce1a28ab78398b585d/html5/thumbnails/27.jpg)
Cure"of"HCV"means"a"lot"to"our"pa,ents
Cachay"et"al."2011,"AIDS"Res"Ther.;8:29"
0" 5" 10" 15" 20" 25"1" 4"3"2" 5" 6"
40"
60"
80"
100"
120"
40"
60"
80"
100"
120"
![Page 28: A Decade of Treating HCV in Patients with Ongoing Barriers to Care](https://reader031.vdocument.in/reader031/viewer/2022030214/588b1cce1a28ab78398b585d/html5/thumbnails/28.jpg)
2011:"HRSA""‘UCSD"CoJinfec,on"Clinic"a"model"to"replicate’
PegUIFN&+&&RBV&
PegUIFN&+&RBV&+&DAA&
DAA&combinaHon&
2016&2011& 2013&2012& 2014& 2015&2010&
Treatment"complexity"
HIV"primary"care/ID"clinics"to"treat"HCV""
2005&
![Page 29: A Decade of Treating HCV in Patients with Ongoing Barriers to Care](https://reader031.vdocument.in/reader031/viewer/2022030214/588b1cce1a28ab78398b585d/html5/thumbnails/29.jpg)
Lesson"#3:"Do"not"do"harm
• Use&of&triple&therapy&with&pegylatedUInterferon&+&Ribavirin&+&Telaprevir&promised&~&75%&chance&of&HCV&cure&
• Following&treatment&of&our&first&25&paHents&with&triple&therapy,&we&observed&something&different:&&
&&‘&One&of&two&paHents&treated&with&HCV&triple&therapy&could&be&cure&of&HCV&…but&at&&the&cost&of&one&in&two&developing&serious&adverse&reacHons&(Grade&III&or&IV)&that&required&hospitalizaHon’.&
Cachay&et&al.&AIDS.&2013;27(18):2893U7.&
![Page 30: A Decade of Treating HCV in Patients with Ongoing Barriers to Care](https://reader031.vdocument.in/reader031/viewer/2022030214/588b1cce1a28ab78398b585d/html5/thumbnails/30.jpg)
HCV"treatment"uptake"at"UCSD"Owen"Clinic"
Cachay et et al. Plos One 2014
2008& 2009& 2010& 2011& 2012&0&
1&
3&
2&
4&
5&
6&
7&
8&
HCV
&treatm
ent&u
ptake&pe
r&100P
YFU&
Copyright © Edward Cachay MD, MAS.
2013&
Mean&
95%&&CI&
2014&
![Page 31: A Decade of Treating HCV in Patients with Ongoing Barriers to Care](https://reader031.vdocument.in/reader031/viewer/2022030214/588b1cce1a28ab78398b585d/html5/thumbnails/31.jpg)
May"2013:
&
• We&advocated&for&IFNUfree&DAA&combinaHons&for&our&paHents,&before&any&professional&guideline&was&available.&
![Page 32: A Decade of Treating HCV in Patients with Ongoing Barriers to Care](https://reader031.vdocument.in/reader031/viewer/2022030214/588b1cce1a28ab78398b585d/html5/thumbnails/32.jpg)
Sofosbuvir:"HCV"vs"HCV/HIV,"in"genotype"1,2"and"3
SOF/P/R&& SOF/R& GT2&naive&
89& 89&
68&
95& 94&90&
93& 91&
0&
10&
20&
30&
40&
50&
60&
70&
80&
90&
100&SV
R"rate"HCV& HIV/HCV&
AnHviral&Drugs&Advisory&Commiqee&MeeHng,&FDA&review,&10/24/13&&C208,&C216,&C206,&C212,&HPC3007,&Dieterich,&14th&European&AIDS&Conference,&2013;&&
Lawitz&et&al.&NEJM&2013&
81&89&
79&88&
GT2&experienced&
GT3&naive& GT3&experienced&
Lesion:&‘HIV&is&no&longer&a&poor&prognosHc&factor&for&response&to&HCV&treatment’&
![Page 33: A Decade of Treating HCV in Patients with Ongoing Barriers to Care](https://reader031.vdocument.in/reader031/viewer/2022030214/588b1cce1a28ab78398b585d/html5/thumbnails/33.jpg)
We"were"looking"forward"to"the"exci,ng",mes"coming"ahead!
IFN& pegIFNURBV& Triple& All&oral&DAA&
Sustaine
d&viral&respo
nse&(cure)&&
1990s& 2000s& 2011& 2014&
10%&
35%&
65%&
>&90%&
No.&
Adapted from Expert Opin Pharmacother. 2013;14:1161-70
Copyright © Edward Cachay MD, MAS.
![Page 34: A Decade of Treating HCV in Patients with Ongoing Barriers to Care](https://reader031.vdocument.in/reader031/viewer/2022030214/588b1cce1a28ab78398b585d/html5/thumbnails/34.jpg)
Treatment"only"helps"those"who"receive"it
100&%& 100&%&& 100&%&
20&%& 20&%&
10&%& 19&%&
90&%&
85&%&
All&HCV&PaHents&
Diagnosis&and&therapy&
Cure&
PegUIFN/RBV& 95%&SVR&95%&SVR,&increase&diagnosis&and&
linkage&to&treatment&
![Page 35: A Decade of Treating HCV in Patients with Ongoing Barriers to Care](https://reader031.vdocument.in/reader031/viewer/2022030214/588b1cce1a28ab78398b585d/html5/thumbnails/35.jpg)
1"pill"of"Sofosbuvir"~"1,000$
![Page 36: A Decade of Treating HCV in Patients with Ongoing Barriers to Care](https://reader031.vdocument.in/reader031/viewer/2022030214/588b1cce1a28ab78398b585d/html5/thumbnails/36.jpg)
Consequences"of"high"price"of"HCV"medica,ons
0&
1&
2&
3&
4&
5&
6&
7&
8&
1& 2& 3& 4&2013&Q4&
Q2& Q3& Q4& 2015&Q1&
2014&
$&Billions&per&month& Sales&>&$&2.5&
billion/month&
Profits&&>&$&1.4&billion/month&
Source:&Gilead&sales,&adapted&from&IDWeeK&2015.&Sunday&11&
![Page 37: A Decade of Treating HCV in Patients with Ongoing Barriers to Care](https://reader031.vdocument.in/reader031/viewer/2022030214/588b1cce1a28ab78398b585d/html5/thumbnails/37.jpg)
• U.S.&is&the&only&country&that&places&no&limit&to&drug&prices&
• Government&grants&drug&patents&under&HatchUWaxman&Act&
• Purpose:&to&incenHvize&development&of&the&drugs&the&public&needs&
• When&these&drugs&are&placed&out&of&reach&of&the&public,&government&needs&to&weight&preventable&morbidity&and&mortality&vs.&company&monopoly&pricing&rights.&
• Federal&law&28&U.S.C.&§&1498&(a)&allows&government&to&use&patent&invenHon&without&permission&of&the&owner.&
![Page 38: A Decade of Treating HCV in Patients with Ongoing Barriers to Care](https://reader031.vdocument.in/reader031/viewer/2022030214/588b1cce1a28ab78398b585d/html5/thumbnails/38.jpg)
The"HCV"market"running"and"their"impact"on"lowering"the"prices"
Gilead"
AbbVie"
BMS"
Janssen"
Merck"
&&&&&&&&&
Roche&Boehringer&
![Page 39: A Decade of Treating HCV in Patients with Ongoing Barriers to Care](https://reader031.vdocument.in/reader031/viewer/2022030214/588b1cce1a28ab78398b585d/html5/thumbnails/39.jpg)
Consequences"of"high"price"in"2014
• Conflict&&between&provider,&paHent&and&payer&over&raHoning&&UU&&“you&must&wait&unHl&you&have&severe&liver&damage&to&g&t&treated”&
&UU&“&You&need&to&be&clean&and&sober&to&be&treated”&&
&UU&“&I&am¬&worth&the&treatment”&
![Page 40: A Decade of Treating HCV in Patients with Ongoing Barriers to Care](https://reader031.vdocument.in/reader031/viewer/2022030214/588b1cce1a28ab78398b585d/html5/thumbnails/40.jpg)
2014:"Payer"restric,ons"(Public"and"private)..aka..
Alcohol&and&substance&use&&
Fibrosis:&Most&state&Medicaid&required&F3/4&&&&&&&&&&&&&&&&6&States&required&liver&biopsies&&
Prescriber&specialtyU&monopoly&&&
Onerous&preUauthorizaHon&procedures:&&&&&&&&&&&&&&&&&&~&12&hours&per&paHent&&
U Contradict&medical&specialty&guidance&
&U Purely&for&financial&reasons&&&U Discriminatory&&U Illegal&&
![Page 41: A Decade of Treating HCV in Patients with Ongoing Barriers to Care](https://reader031.vdocument.in/reader031/viewer/2022030214/588b1cce1a28ab78398b585d/html5/thumbnails/41.jpg)
HCV is the only disease where there has to be significant organ damage to treat.
Ann Intern Med. 2013;158(9):658-666.
Persons with HIV had liver fibrosis measurements equal to those of persons without HIV, who were, on average, 9.2 years older
![Page 42: A Decade of Treating HCV in Patients with Ongoing Barriers to Care](https://reader031.vdocument.in/reader031/viewer/2022030214/588b1cce1a28ab78398b585d/html5/thumbnails/42.jpg)
REVEALJHCV:"‘HCV"is"a"systemic"infec,on’"
Lee"et"al."J"Infect"Dis"2012;"206:"469J77.""
2.8
1.5
1.3
1.4
5.4
21.6
12.5
1.9
//
All causes death Liver-related
Liver cancer
Cirrhosis
Extrahepatic Cancers*
Cardiovascular
Kidney
Adjusted hazard ratios
HCV Ab-pos vs HCV Ab-neg
U 23,820"adults"followed"for"a"mean"of"16.2"years"U 1095"HCV"Ab+"(4%)"U 69%"of"HCV"Ab+"were"HCVGRNA"pos"U 2394"deaths"during"the"study"period"
*esophagus, prostate & thyroid
![Page 43: A Decade of Treating HCV in Patients with Ongoing Barriers to Care](https://reader031.vdocument.in/reader031/viewer/2022030214/588b1cce1a28ab78398b585d/html5/thumbnails/43.jpg)
""Hepa,,s"C"surpasses"HIV"as"a"cause"of"death"in"the"US"
Rate"per""100"000"Persons"
2000"1999" 2001" 2002" 2003" 2004" 2005" 2006" 2007"
Hepa((s"B"
Hepa((s"C"
HIV"
adapted from Ann Intern Med. 2012, 156:271-8
0&1&
2&
3&
4&
5&
6&
7&
HIV" Chronic"liver"disease"
Alcohol"related"condi(ons" Hepa((s"B"
&1.8&(1.6&U2.0)& 32.1&(31.0U33.3)& 4.6&(4.4&U4.8)& 29.9&(26.5U33.6)&
Why&do&we&have&to&exclude&people&who&use&drugs&or&alcohol?&
![Page 44: A Decade of Treating HCV in Patients with Ongoing Barriers to Care](https://reader031.vdocument.in/reader031/viewer/2022030214/588b1cce1a28ab78398b585d/html5/thumbnails/44.jpg)
The"most"frequent"reason"for"not"ini,a,ng"HCV"therapy"is"the"presence"of"ongoing"barriers"to"care"in"the"IFNJera
Known"HCV"infec,on"with"established"HIV"care 100%"(n=751)"
Referred"for"HCV"treatment" 40%"(n=301)"
AMended"≥"1"clinic"visit"for"HCV"evalua,on" 37%"(n=281)"
Final"decision"is"made"regarding" HCV"therapy"ini,a,on
33%"(n=248)"
Start"HCV"treatment "12%"(n=88)"
""""HCV"cure" """""5%(n=41)"
Cachay"et"al."PLoS"One."2014";9:e102883
&&&&&&&&U&Barriers&to&care:&78&of&195&(40%)&U&PaHent&did¬&want&IFNUbased®imens:&45&of&195&(23%)&U&Advanced&liver&disease:&34&of&195(18%)&&U&Prior&null&response&:&16&of&195(8%)&U&Spontaneous&clearance:&16&of&195(8%)&U&ContraindicaHon&to&IFN/or&RBV:&6&of&195(3%)&
Reasons&for¬&starHng&HCV&treatment:&
![Page 45: A Decade of Treating HCV in Patients with Ongoing Barriers to Care](https://reader031.vdocument.in/reader031/viewer/2022030214/588b1cce1a28ab78398b585d/html5/thumbnails/45.jpg)
Where"do"we"stand"in"this"fight?" MedicaHon&manufacturer& InsurancesU&
Health&payees&
![Page 46: A Decade of Treating HCV in Patients with Ongoing Barriers to Care](https://reader031.vdocument.in/reader031/viewer/2022030214/588b1cce1a28ab78398b585d/html5/thumbnails/46.jpg)
Nothing"speaks"beMer"than"data"and"that"is"the"best"way"to"advocate"for"our"pa,ents
![Page 47: A Decade of Treating HCV in Patients with Ongoing Barriers to Care](https://reader031.vdocument.in/reader031/viewer/2022030214/588b1cce1a28ab78398b585d/html5/thumbnails/47.jpg)
HCV"treatment"regimens"used"in"HIV"coJinfected"pa,ents"in"2014"at"UCSD
Genotype" N"="30" Regimens"1a& &23& &&&RBV&+&SOFU24&weeks&&&&&&&&&&&&&&&&&&&&&&&&&&&&(&2)&
&&&SIM&+&SOFU12&weeks&&&&&&&&&&&&&&&&&&&&&&&&&&&&(12)&&&&SIM&+&SOFU24&weeks&&&&&&&&&&&&&&&&&&&&&&&&&&&&(&4)&&&&SIM&+&SOF&+&RBVU24&&weeks&&&&&&&&&&&&&&&&(&1)&&&&LDV&+&SOFU12&weeks&&&&&&&&&&&&&&&&&&&&&&&&&&&&(&2)&&&&LDV&+&SOFU24&&weeks&&&&&&&&&&&&&&&&&&&&&&&&&&&(&2)&
2& &3& &&&SOF+RBVU12&weeks&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&(&3)&
3& &2& &&&SOF+RBVU24&weeks&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&(&2)&
4& &2& &&&SIMF+SOF&+&RBVU12&weeks&&&&&&&&&&&&&&&&&(&1)&&&&SIM&+&SOFU24&weeks&&&&&&&&&&&&&&&&&&&&&&&&&&&&&(&1)&
Cachay et et al. OFID under review
![Page 48: A Decade of Treating HCV in Patients with Ongoing Barriers to Care](https://reader031.vdocument.in/reader031/viewer/2022030214/588b1cce1a28ab78398b585d/html5/thumbnails/48.jpg)
Characteris,cs"of"pa,ents"with"cirrhosis"("n=22)
Genotype&"""X""&
&&&&&&&&&&1a&&&&&&&&&&&2&&&&&&&&&&&4&
&&&&19&(86%)&&&&&&1&(5%)&&&&&&&2&(9%)&
Median&&MELD&score&&(range)& &&&11&(6U20)&Prior"liver"decompensa(on""&&Ascites&&&&HepaHc&encephalopathy&&&&Esophageal&varices&bleeding&&
10"&9&&7&&&3&
Cachay et et al. OFID under review
![Page 49: A Decade of Treating HCV in Patients with Ongoing Barriers to Care](https://reader031.vdocument.in/reader031/viewer/2022030214/588b1cce1a28ab78398b585d/html5/thumbnails/49.jpg)
"90%"of"our"treated"pa,ents"will"not"fulffil"clinical"trial"enrollment""
5&
2& 2& 2&
4&
2&
Comorbilidad& Barreras&de&salud&
TARGA&compleja&+&comorbilidad&
comorbilidad&+&barreras&de&
salud&
TARGA&compleja&+&barreras&+&
comorbilidad&
Child&CUcirrosis&
Cirrho(cs"pa(ents"with"GT"1a"(n=17)"
Comorbidity&& Barriers&to&care&
Complex&ART&&+&
&comorbidity&
Comorbidity&+&&
Barriers&to&care&
Complex&ART&&+&
Barriers&+&
&comorbidity&
Child&C&Cirrhosis&&
Cachay et et al. OFID under review
![Page 50: A Decade of Treating HCV in Patients with Ongoing Barriers to Care](https://reader031.vdocument.in/reader031/viewer/2022030214/588b1cce1a28ab78398b585d/html5/thumbnails/50.jpg)
0
75 83.34
SMV + SOF± RBV x 12 Wks
Real"world
. 1Dieterich D, et al. AASLD 2014. Abstract 46.
n =
UCSD
SV
R 4
(%)
100
80
60
40
20
COSMOS F3/F4
N=&145& N=&30&N=&13&
93 89.6
N=&29&
TRIO&
Mt"Sinai
81.08
N=&37&
"Penns."/"New"Jersey
N=33&
83.03
Northwest
HIV&cohorts&
90
80
Cachay et et al. OFID under review
![Page 51: A Decade of Treating HCV in Patients with Ongoing Barriers to Care](https://reader031.vdocument.in/reader031/viewer/2022030214/588b1cce1a28ab78398b585d/html5/thumbnails/51.jpg)
What"is"the"impact"of"barriers"to"care"on"HCV"treatment"response?"
• Ongoing&barriers&to&care&&definiHon:&drug/alcohol&use,&homelessness&,&poverty&and&neuropsychiatry&disease.&
• RetrospecHve&comparison&of&all&paHents&treated&an&Owen&HCV&clinic&
• Our&treatment&protocol&for&treaHng&HCV&among&paHents&with&barriers&to&care&has&been&unchanged&since&clinic&incepHon&(2008),&we&compared&treatment&outcomes&across&HCV&treatment&era&:&
&&&&U&Dual&therapy&(pegylated&interferon&plus&ribavirin,&2008U2011);&&
&&&&U&Triple&therapy&(pegUIFN&plus&ribavirin&and&telaprevir,&2011U2013);&&
&&&&U&IFNUfree&DAA&therapy&(2014&)&
![Page 52: A Decade of Treating HCV in Patients with Ongoing Barriers to Care](https://reader031.vdocument.in/reader031/viewer/2022030214/588b1cce1a28ab78398b585d/html5/thumbnails/52.jpg)
Cachay et et al. IDweek 2015- abstract 1672
![Page 53: A Decade of Treating HCV in Patients with Ongoing Barriers to Care](https://reader031.vdocument.in/reader031/viewer/2022030214/588b1cce1a28ab78398b585d/html5/thumbnails/53.jpg)
Cachay et et al. IDweek 2015- abstract 1672
![Page 54: A Decade of Treating HCV in Patients with Ongoing Barriers to Care](https://reader031.vdocument.in/reader031/viewer/2022030214/588b1cce1a28ab78398b585d/html5/thumbnails/54.jpg)
Results:"
• HCV&eradicaHon&among&paHents&with&ongoing&barriers&to&care&improved&from&40%&(95%&CI:&21U61)&to&75%&(95%&CI:&48U93)&in&the&dual&and&DAA&eras,&respecHvely.&
• Using&DAA&and&an&inclusive&HCV&treatment&protocol&75%&of&HIV/HCV&treated&paHents&with&ongoing&barriers&to&care&achieved&HCV&eradicaHon.&
![Page 55: A Decade of Treating HCV in Patients with Ongoing Barriers to Care](https://reader031.vdocument.in/reader031/viewer/2022030214/588b1cce1a28ab78398b585d/html5/thumbnails/55.jpg)
S,ll"much"remains"to"be"done
![Page 56: A Decade of Treating HCV in Patients with Ongoing Barriers to Care](https://reader031.vdocument.in/reader031/viewer/2022030214/588b1cce1a28ab78398b585d/html5/thumbnails/56.jpg)
Conclusions:
• A&HIV&primary&care&model&is&a&effecHve&way&to&increase&HCV&treatment&uptake&among&HIVUinfected&paHents.&
• Our&data&supports&that&HIVUinfected&paHents&with&ongoing&barriers&to&care&(e.g.&drug/alcohol&use)&achieve&similar&proporHons&of&HCV&cure&than&paHents&without&barriers&to&care&&if&they&seek&voluntarily&HCV&treatment.&
• We&need&collaboraHons&of&all&fronts&in&our&society&to&effecHvely&treat&HCV&in&our&paHents:&Pharma,&Public&payers,&Local&&&federal&government.&&
![Page 57: A Decade of Treating HCV in Patients with Ongoing Barriers to Care](https://reader031.vdocument.in/reader031/viewer/2022030214/588b1cce1a28ab78398b585d/html5/thumbnails/57.jpg)
Acknowledgements
U Christopher&Mathews&
U Chuck&Hicks&U Robert&Schooley&U Alex&Kuo&&U My&Owen&colleagues&
U Jerry&Collins&U Susan&McQuillen&
&&
• Owen&HCV&team&U&Craig&Ballard&
U&David&Wyles&
U Bradford&Colwell&U Francesca&Torriani&U Miguel&Goicoechea&(2008U2011)&
U Lucas&Hill&
![Page 58: A Decade of Treating HCV in Patients with Ongoing Barriers to Care](https://reader031.vdocument.in/reader031/viewer/2022030214/588b1cce1a28ab78398b585d/html5/thumbnails/58.jpg)
People&with&ongoing&barriers&to&care&are&a&reflecHon&of&us&as&society.&They&provide&us&the&opportunity&to&look&at&the&place&where&we&live&from&a&different&perspecHve.&Working&together&with&tolerance&and&inclusion&are&key&to&promote&the&common&good&of&everyone&in&our&society.&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&Edward&Cachay&